Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type |Pathology location|Pathology Description|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology 
|4-1-1-1|1|463|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-2|1|500|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-3|1|561|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-4|1|570|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-5|1|577|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-6|1|601|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-7|1|609|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-8|1|635|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-9|1|648|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-10|1|649|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-11|1|657|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-12|1|668|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-13|1|684|Neoplasia benign|Integumentary system,MA: 0000151 - skin|trichoepithelioma,MPATH: 218 - neoplasm|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-14|1|684|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-15|1|689|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-16|1|691|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-17|1|703|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-18|1|705|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-19|1|710|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-20|1|710|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-21|1|718|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-22|1|720|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-23|1|726|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-24|1|728|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-25|1|731|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-26|1|740|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-27|1|761|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-28|1|768|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-29|1|772|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|horned,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-30|1|780|Neoplasia malignant|Other local manifestations and miscellaneus|axilla|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-31|1|787|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-32|1|792|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-33|1|794|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-34|1|799|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-35|1|802|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-36|1|805|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-37|1|807|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-38|1|808|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-39|1|812|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-40|1|820|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-41|1|820|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-42|1|825|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-43|1|826|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-44|1|831|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 270 - adenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-45|1|833|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-46|1|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-47|1|843|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-48|1|848|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-49|1|850|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-50|1|851|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-51|1|857|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-52|1|865|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|fibroma,MPATH: 218 - neoplasm|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-53|1|867|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-54|1|867|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-55|1|873|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-56|1|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-57|1|879|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-58|1|891|Neoplasia malignant|Other local manifestations and miscellaneus|legs|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-59|1|894|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-60|1|899|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-61|1|900|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|cavity,MPATH: 513 - Lymphoid neoplasms|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-62|1|905|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-63|1|907|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-64|1|909|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-65|1|949|Neoplasia benign|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 277 - cystadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-66|1|965|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-67|1|969|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-68|1|976|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-69|1|992|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-70|1|994|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-71|1|995|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-72|1|1001|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-73|1|1006|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-74|1|1011|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-75|1|1013|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-76|1|1028|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-77|1|1034|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-78|1|1034|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-79|1|1050|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-80|1|1055|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-81|1|1058|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-82|1|1063|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-83|1|1070|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-84|1|1078|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-85|1|1084|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|mesenterium,MPATH: 408 - soft tissue fibrosarcoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-86|1|1089|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-87|1|1096|Other deterministic changes|Whole body|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-88|1|1110|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|face,MPATH: 446 - squamous cell carcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-89|1|1135|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|face,MPATH: 446 - squamous cell carcinoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-90|1|1144|Neoplasia malignant|Other local manifestations and miscellaneus|inquinal|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-91|1|1158|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-92|1|1180|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-93|1|1182|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-94|1|1194|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-1|Na600-Do 0,n/a|1| 84|saline control|600|microliters|Injection, intravenous| saline control|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-1-95|1|1249|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-1|2|183|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-2|2|199|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-3|2|432|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-4|2|479|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-5|2|485|Neoplasia malignant|Other local manifestations and miscellaneus|adrenals|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-6|2|530|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-7|2|548|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-8|2|560|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-9|2|565|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-10|2|621|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-11|2|632|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-12|2|649|Neoplasia malignant|Other local manifestations and miscellaneus|cavity|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-13|2|649|Neoplasia malignant|Other local manifestations and miscellaneus|cavity|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-14|2|692|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-15|2|698|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-16|2|704|Neoplasia benign|Bloodvessels among cardiovascular system|lymphnode|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-17|2|711|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-18|2|718|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-19|2|720|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-20|2|749|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-21|2|763|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-22|2|778|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-23|2|778|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-24|2|792|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-25|2|792|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-26|2|804|Neoplasia benign|Other local manifestations and miscellaneus|neck|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-27|2|805|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-28|2|806|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-29|2|806|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-30|2|808|Neoplasia benign|Other local manifestations and miscellaneus|intestine|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-31|2|818|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-32|2|818|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-33|2|820|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-34|2|822|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-35|2|822|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-36|2|826|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-37|2|835|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-38|2|837|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-39|2|837|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 551 - sarcoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-40|2|839|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-41|2|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-42|2|858|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-43|2|863|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 270 - adenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-44|2|869|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-45|2|871|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-46|2|872|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-47|2|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|hindlegs,MPATH: 513 - Lymphoid neoplasms|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-48|2|878|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-49|2|891|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-50|2|901|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-51|2|907|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-52|2|909|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-53|2|921|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-54|2|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-55|2|926|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-56|2|927|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-57|2|934|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-58|2|934|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-59|2|942|Neoplasia systemic|Haematolymphatic system|liver|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-60|2|942|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-61|2|943|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-62|2|944|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|carcinose,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-63|2|944|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-64|2|947|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-65|2|948|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-66|2|948|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-67|2|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-68|2|964|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-69|2|972|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-70|2|979|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-71|2|980|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-72|2|992|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-73|2|993|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-74|2|995|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-75|2|1007|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-76|2|1008|Neoplasia benign|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 270 - adenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-77|2|1027|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|papilloma,MPATH: 218 - neoplasm|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-78|2|1029|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-79|2|1042|Neoplasia benign|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 270 - adenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-80|2|1046|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-81|2|1051|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-82|2|1056|Neoplasia benign|Other local manifestations and miscellaneus|cavity|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-83|2|1062|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-84|2|1078|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-85|2|1082|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-86|2|1084|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-87|2|1091|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-88|2|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-89|2|1122|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-90|2|1128|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-91|2|1147|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 270 - adenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-92|2|1150|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-93|2|1183|Other deterministic changes|Whole body|n/a|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-94|2|1192|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-95|2|1196|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|type,MPATH: 218 - neoplasm|
4-1-2|De60-Do 0,n/a|1| 84|dextrine control|60|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-2-96|2|1249|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-1|3|312|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-2|3|437|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-3|3|452|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-4|3|453|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-5|3|457|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-6|3|496|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-7|3|512|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-8|3|539|Other deterministic changes|Whole body|face|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-9|3|560|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-10|3|589|Neoplasia unclassified|Central nervous system among nervous system|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-11|3|614|Neoplasia malignant|Other local manifestations and miscellaneus|anal|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-12|3|615|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-13|3|644|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-14|3|648|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-15|3|659|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-16|3|673|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-17|3|673|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-18|3|678|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-19|3|681|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-20|3|693|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-21|3|696|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-22|3|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-23|3|728|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-24|3|732|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-25|3|757|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-26|3|761|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-27|3|763|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-28|3|768|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-29|3|773|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-30|3|778|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 270 - adenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-31|3|778|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-32|3|785|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-33|3|786|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-34|3|789|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-35|3|792|Neoplasia benign|Integumentary system,MA: 0000151 - skin|hindlegs,MPATH: 218 - neoplasm|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-36|3|796|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-37|3|796|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-38|3|807|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|ear,MPATH: 446 - squamous cell carcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-39|3|819|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-40|3|822|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-41|3|827|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-42|3|835|Neoplasia benign|Other local manifestations and miscellaneus|vagina|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-43|3|837|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-44|3|839|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-45|3|844|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-46|3|853|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-47|3|864|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-48|3|865|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-49|3|865|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-50|3|874|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-51|3|879|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-52|3|879|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-53|3|880|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-54|3|898|Neoplasia malignant|Other local manifestations and miscellaneus|face|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-55|3|900|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-56|3|902|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-57|3|906|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-58|3|911|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-59|3|926|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-60|3|927|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-61|3|936|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-62|3|936|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-63|3|949|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-64|3|952|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-65|3|955|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-66|3|970|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-67|3|973|Neoplasia benign|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 270 - adenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-68|3|979|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-69|3|979|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-70|3|980|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-71|3|985|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-72|3|991|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-73|3|995|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-74|3|998|Neoplasia benign|Bloodvessels among cardiovascular system|cavity|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-75|3|1001|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-76|3|1013|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-77|3|1019|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-78|3|1040|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-79|3|1041|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-80|3|1043|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-81|3|1046|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-82|3|1046|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-83|3|1056|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-84|3|1057|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|polyp,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-85|3|1062|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-86|3|1063|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-87|3|1067|Neoplasia benign|Other local manifestations and miscellaneus|cavity|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-88|3|1077|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-89|3|1086|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-90|3|1087|Other deterministic changes|Whole body|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-91|3|1097|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|hindlegs,MPATH: 446 - squamous cell carcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-92|3|1106|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-93|3|1133|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-94|3|1201|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-95|3|1249|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-3|De120-Do 0,n/a|1| 84|dextrine control|120|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-3-96|3|1249|Neoplasia benign|Other local manifestations and miscellaneus|cavity|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-1|4|248|Neoplasia unclassified|Peripheral nerves  among nervous system|cavity|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-2|4|360|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-3|4|397|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-4|4|450|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-5|4|469|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-6|4|542|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-7|4|568|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-8|4|580|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-9|4|605|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-10|4|614|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-11|4|629|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-12|4|644|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-13|4|655|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-14|4|664|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-15|4|688|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-16|4|691|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-17|4|691|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-18|4|698|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-19|4|699|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-20|4|707|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-21|4|709|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-22|4|722|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-23|4|726|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-24|4|731|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-25|4|731|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|anal,MPATH: 408 - soft tissue fibrosarcoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-26|4|733|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-27|4|735|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-28|4|740|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-29|4|749|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-30|4|753|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-31|4|754|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-32|4|755|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-33|4|763|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-34|4|763|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-35|4|776|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-36|4|778|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-37|4|783|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-38|4|784|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|horned,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-39|4|793|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-40|4|796|Neoplasia systemic|Haematolymphatic system|liver|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-41|4|796|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-42|4|798|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-43|4|805|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-44|4|813|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-45|4|818|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-46|4|819|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-47|4|819|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-48|4|820|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-49|4|826|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-50|4|831|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-51|4|836|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-52|4|844|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 270 - adenoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-53|4|846|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-54|4|851|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-55|4|855|Neoplasia benign|Integumentary system,MA: 0000151 - skin|hindlegs,MPATH: 218 - neoplasm|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-56|4|876|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-57|4|878|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-58|4|883|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-59|4|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-60|4|886|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-61|4|893|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-62|4|923|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-63|4|926|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-64|4|929|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-65|4|929|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|thorax,MPATH: 408 - soft tissue fibrosarcoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-66|4|930|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-67|4|931|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-68|4|936|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-69|4|937|Neoplasia benign|Other local manifestations and miscellaneus|cavity|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-70|4|940|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-71|4|944|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-72|4|958|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-73|4|959|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-74|4|963|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|appendix,MPATH: 513 - Lymphoid neoplasms|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-75|4|972|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-76|4|976|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-77|4|986|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|anal,MPATH: 446 - squamous cell carcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-78|4|1000|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-79|4|1009|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-80|4|1024|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-81|4|1075|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-82|4|1079|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-83|4|1086|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-84|4|1091|Neoplasia malignant|Other local manifestations and miscellaneus|neck|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-85|4|1093|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-86|4|1106|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-87|4|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-88|4|1126|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-89|4|1135|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-90|4|1137|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-91|4|1147|Other deterministic changes|Whole body|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-92|4|1157|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-93|4|1160|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-94|4|1197|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-4|De300-Do 0,n/a|1| 84|dextrine control|300|microliters|Injection, intravenous| dextrin control|96 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-4-95|4|1249|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-1|5|313|Neoplasia benign|Other local manifestations and miscellaneus,MA: 0000003 - organ system|cavity,MPATH: 322 - teratoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-2|5|374|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-3|5|476|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-4|5|501|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-5|5|509|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|mediastinum,MPATH: 408 - soft tissue fibrosarcoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-6|5|541|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-7|5|547|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-8|5|569|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-9|5|585|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-10|5|591|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-11|5|607|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-12|5|643|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-13|5|679|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-14|5|684|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-15|5|698|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-16|5|698|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-17|5|703|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-18|5|707|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-19|5|711|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-20|5|713|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-21|5|735|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|face,MPATH: 446 - squamous cell carcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-22|5|749|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-23|5|749|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-24|5|760|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-25|5|760|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-26|5|768|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-27|5|770|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-28|5|772|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-29|5|792|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-30|5|799|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-31|5|813|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-32|5|815|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-33|5|817|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-34|5|822|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-35|5|825|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-36|5|825|Neoplasia malignant|Other local manifestations and miscellaneus|origin|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-37|5|826|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-38|5|834|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-39|5|835|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-40|5|844|Neoplasia benign|Integumentary system,MA: 0000151 - skin|forelegs,MPATH: 218 - neoplasm|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-41|5|848|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-42|5|850|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-43|5|855|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-44|5|862|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-45|5|864|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-46|5|872|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-47|5|872|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-48|5|881|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-49|5|885|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-50|5|885|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-51|5|902|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-52|5|904|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-53|5|904|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-54|5|905|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-55|5|916|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-56|5|920|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-57|5|922|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-58|5|925|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-59|5|930|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-60|5|942|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-61|5|944|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-62|5|949|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-63|5|955|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-64|5|964|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|polyp,MPATH: 218 - neoplasm|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-65|5|969|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-66|5|983|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-67|5|983|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-68|5|986|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-69|5|988|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-70|5|991|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-71|5|993|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-72|5|1024|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-73|5|1044|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-74|5|1056|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-75|5|1079|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-76|5|1082|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-77|5|1084|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-78|5|1084|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-79|5|1085|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-80|5|1099|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-81|5|1107|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-82|5|1113|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-83|5|1120|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-84|5|1121|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-85|5|1143|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-86|5|1154|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-87|5|1168|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-88|5|1169|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-89|5|1171|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-90|5|1178|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-91|5|1189|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-92|5|1190|Other deterministic changes|Whole body|n/a|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-93|5|1241|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-94|5|1249|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-95|5|1249|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|polype,MPATH: 266 - fibroadenoma|
4-1-5|De600-Do 0,n/a|1| 84|dextrine control|600|microliters|Injection, intravenous| dextrin control|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-5-96|5|1249|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-1|6|298|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-2|6|342|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-3|6|354|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-4|6|418|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-5|6|542|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-6|6|582|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-7|6|591|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-8|6|602|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-9|6|606|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-10|6|611|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|anal,MPATH: 408 - soft tissue fibrosarcoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-11|6|612|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-12|6|615|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-13|6|619|Neoplasia benign|Other local manifestations and miscellaneus|cavity|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-14|6|622|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-15|6|639|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-16|6|658|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-17|6|663|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-18|6|665|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-19|6|697|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-20|6|704|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-21|6|705|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-22|6|712|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-23|6|713|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|inquinal,MPATH: 408 - soft tissue fibrosarcoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-24|6|720|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-25|6|726|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-26|6|749|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-27|6|756|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-28|6|759|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-29|6|763|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-30|6|763|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-31|6|764|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-32|6|770|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-33|6|770|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-34|6|779|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-35|6|787|Neoplasia malignant|Other local manifestations and miscellaneus|inquinal|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-36|6|799|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|tail,MPATH: 408 - soft tissue fibrosarcoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-37|6|799|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-38|6|806|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-39|6|813|Neoplasia benign|Lower respiratory system|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-40|6|819|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-41|6|826|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-42|6|829|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-43|6|834|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-44|6|836|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|thorax,MPATH: 408 - soft tissue fibrosarcoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-45|6|840|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-46|6|857|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-47|6|865|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-48|6|870|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-49|6|871|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-50|6|877|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-51|6|878|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-52|6|883|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-53|6|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-54|6|891|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-55|6|893|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-56|6|909|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-57|6|914|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-58|6|918|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-59|6|927|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-60|6|935|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-61|6|937|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-62|6|954|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-63|6|958|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-64|6|960|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-65|6|962|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-66|6|965|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-67|6|980|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-68|6|984|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-69|6|994|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-70|6|997|Neoplasia benign|Other local manifestations and miscellaneus|foot|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-71|6|1006|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-72|6|1013|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-73|6|1026|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-74|6|1035|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-75|6|1035|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|papilloma,MPATH: 218 - neoplasm|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-76|6|1038|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-77|6|1040|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-78|6|1045|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-79|6|1046|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-80|6|1049|Neoplasia benign|Other local manifestations and miscellaneus|cavity|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-81|6|1053|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-82|6|1057|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-83|6|1065|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-84|6|1067|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-85|6|1071|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-86|6|1074|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-87|6|1094|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-88|6|1107|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-89|6|1114|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-90|6|1121|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-91|6|1149|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-92|6|1152|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-93|6|1159|Other deterministic changes|Whole body|n/a|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-94|6|1200|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-6|Th60-Do 1,n/a|1| 84|Th-232 colloid (Thorotrast)|1|relative dose rate|Injection, intravenous| 60l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-6-95|6|1249|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-1|7|455|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-2|7|527|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-3|7|532|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-4|7|554|Neoplasia benign|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 270 - adenoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-5|7|565|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-6|7|597|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-7|7|605|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-8|7|613|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-9|7|629|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-10|7|635|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-11|7|640|Neoplasia benign|Integumentary system,MA: 0000151 - skin|chin,MPATH: 218 - neoplasm|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-12|7|649|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-13|7|650|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-14|7|671|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-15|7|682|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-16|7|696|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-17|7|697|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|carcinosarcoma,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-18|7|699|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-19|7|710|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-20|7|711|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-21|7|717|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-22|7|721|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-23|7|728|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-24|7|742|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-25|7|749|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-26|7|755|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-27|7|757|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-28|7|772|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-29|7|775|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-30|7|779|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|fibroma,MPATH: 218 - neoplasm|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-31|7|787|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-32|7|799|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-33|7|799|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-34|7|802|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-35|7|802|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-36|7|803|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-37|7|815|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-38|7|815|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-39|7|825|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-40|7|827|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-41|7|836|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-42|7|840|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-43|7|842|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-44|7|864|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-45|7|866|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-46|7|870|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-47|7|874|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-48|7|883|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-49|7|887|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-50|7|891|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-51|7|894|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-52|7|899|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-53|7|904|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-54|7|911|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-55|7|911|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|hindlegs,MPATH: 513 - Lymphoid neoplasms|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-56|7|913|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-57|7|914|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-58|7|936|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-59|7|943|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-60|7|945|Neoplasia benign|Integumentary system,MA: 0000151 - skin|forelegs,MPATH: 407 - fibroma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-61|7|945|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-62|7|956|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-63|7|958|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-64|7|965|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-65|7|967|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-66|7|967|Neoplasia unclassified|Peripheral nerves  among nervous system|ovary|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-67|7|970|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-68|7|979|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-69|7|981|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-70|7|981|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-71|7|1000|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-72|7|1012|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-73|7|1015|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-74|7|1019|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-75|7|1023|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-76|7|1028|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-77|7|1030|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-78|7|1036|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-79|7|1037|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-80|7|1049|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-81|7|1055|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-82|7|1055|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|anal,MPATH: 446 - squamous cell carcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-83|7|1067|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-84|7|1067|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|polyp,MPATH: 266 - fibroadenoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-85|7|1084|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-86|7|1086|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-87|7|1090|Neoplasia unclassified|Central nervous system among nervous system|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-88|7|1099|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-89|7|1108|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-90|7|1112|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-91|7|1134|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-92|7|1143|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-93|7|1163|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-94|7|1198|Other deterministic changes|Whole body|n/a|
4-1-7|Th120-Do 2,n/a|1| 84|Th-232 colloid (Thorotrast)|2|relative dose rate|Injection, intravenous| 120l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-7-95|7|1205|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-1|8|424|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-2|8|425|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-3|8|441|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-4|8|477|Neoplasia malignant|Other local manifestations and miscellaneus|cavity|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-5|8|496|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-6|8|522|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-7|8|541|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-8|8|542|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-9|8|546|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-10|8|572|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-11|8|600|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-12|8|628|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-13|8|634|Neoplasia unclassified|Central nervous system among nervous system|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-14|8|635|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-15|8|644|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-16|8|665|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-17|8|673|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-18|8|679|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-19|8|684|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-20|8|691|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-21|8|697|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-22|8|704|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|ear,MPATH: 446 - squamous cell carcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-23|8|710|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-24|8|711|Neoplasia unclassified|Peripheral nerves  among nervous system|inquinal|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-25|8|733|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-26|8|742|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-27|8|745|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-28|8|746|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-29|8|748|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-30|8|748|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-31|8|750|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-32|8|756|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-33|8|763|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-34|8|766|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|eye,MPATH: 446 - squamous cell carcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-35|8|772|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-36|8|775|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-37|8|775|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-38|8|782|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-39|8|782|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-40|8|789|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-41|8|789|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-42|8|790|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 270 - adenoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-43|8|799|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-44|8|803|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-45|8|806|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-46|8|813|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-47|8|817|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-48|8|819|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-49|8|844|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-50|8|847|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-51|8|858|Neoplasia unclassified|Peripheral nerves  among nervous system|tail|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-52|8|861|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|tail,MPATH: 408 - soft tissue fibrosarcoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-53|8|862|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-54|8|870|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-55|8|870|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-56|8|874|Other deterministic changes|Whole body|back|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-57|8|878|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-58|8|885|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-59|8|886|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-60|8|887|Neoplasia benign|Bloodvessels among cardiovascular system|lymphnode|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-61|8|888|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|horned,MPATH: 549 - carcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-62|8|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-63|8|899|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-64|8|902|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-65|8|905|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-66|8|905|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-67|8|909|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-68|8|920|Neoplasia malignant|Other local manifestations and miscellaneus|hindlegs|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-69|8|921|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-70|8|921|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-71|8|934|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-72|8|937|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-73|8|938|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-74|8|947|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-75|8|950|Neoplasia benign|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 270 - adenoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-76|8|951|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-77|8|964|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-78|8|972|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-79|8|972|Neoplasia unclassified|Ovary among reproductive system diseases|Thecoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-80|8|976|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|lymphnode,MPATH: 408 - soft tissue fibrosarcoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-81|8|985|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-82|8|1004|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-83|8|1014|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-84|8|1017|Neoplasia malignant|Other local manifestations and miscellaneus|intestine|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-85|8|1019|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-86|8|1030|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-87|8|1034|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-88|8|1067|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-89|8|1096|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-90|8|1098|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-91|8|1099|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-92|8|1111|Other deterministic changes|Whole body|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-93|8|1161|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-94|8|1164|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-95|8|1171|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-1-8|Th300-Do 5,n/a|1| 84|Th-232 colloid (Thorotrast)|5|relative dose rate|Injection, intravenous| 300l from 895 l Th232|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-8-96|8|1335|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|face,MPATH: 446 - squamous cell carcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-1|9|213|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-2|9|419|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-3|9|426|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-4|9|450|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|,MPATH: 551 - sarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-5|9|457|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-6|9|472|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-7|9|476|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-8|9|486|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|cavity,MPATH: 408 - soft tissue fibrosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-9|9|495|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-10|9|530|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-11|9|550|Neoplasia malignant|Other local manifestations and miscellaneus|anal|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-12|9|557|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-13|9|557|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-14|9|561|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-15|9|572|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-16|9|575|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-17|9|585|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-18|9|605|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-19|9|635|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-20|9|636|Neoplasia benign|Other local manifestations and miscellaneus|ovary|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-21|9|644|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-22|9|647|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 74 - hamartoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-23|9|652|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-24|9|658|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-25|9|663|Neoplasia malignant|Other local manifestations and miscellaneus|cavity|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-26|9|663|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-27|9|664|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-28|9|676|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-29|9|689|Neoplasia systemic|Haematolymphatic system|liver|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-30|9|695|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-31|9|705|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-32|9|706|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-33|9|711|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-34|9|713|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|foot,MPATH: 408 - soft tissue fibrosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-35|9|713|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-36|9|727|Neoplasia malignant|Other local manifestations and miscellaneus|foot|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-37|9|732|Neoplasia benign|Bloodvessels among cardiovascular system|lymphnode|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-38|9|733|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-39|9|742|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|tail,MPATH: 408 - soft tissue fibrosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-40|9|748|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-41|9|756|Neoplasia malignant|Other local manifestations and miscellaneus|origin|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-42|9|756|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-43|9|763|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-44|9|763|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-45|9|770|Neoplasia benign|Lower respiratory system|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-46|9|773|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-47|9|777|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-48|9|778|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-49|9|784|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-50|9|790|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-51|9|799|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-52|9|806|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-53|9|813|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-54|9|813|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-55|9|815|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-56|9|818|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-57|9|820|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|ear,MPATH: 408 - soft tissue fibrosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-58|9|820|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-59|9|821|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-60|9|824|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-61|9|826|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-62|9|832|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-63|9|840|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-64|9|844|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-65|9|846|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-66|9|850|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-67|9|856|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-68|9|857|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-69|9|857|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-70|9|862|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-71|9|863|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-72|9|865|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-73|9|869|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-74|9|880|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|cavity,MPATH: 408 - soft tissue fibrosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-75|9|881|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-76|9|890|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-77|9|898|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-78|9|900|Neoplasia malignant|Other local manifestations and miscellaneus|anal|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-79|9|914|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-80|9|944|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-81|9|949|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-82|9|951|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|carcinoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-83|9|954|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|intestine,MPATH: 513 - Lymphoid neoplasms|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-84|9|958|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-85|9|960|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-86|9|964|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-87|9|966|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-88|9|967|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-89|9|969|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-90|9|980|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|anal,MPATH: 219 - adnexal and skin appendage tumor|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-91|9|983|Neoplasia benign|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 270 - adenoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-92|9|1011|Other deterministic changes|Whole body|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-93|9|1034|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-94|9|1108|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-9|Th600-Do10,n/a|1| 84|Th-232 colloid (Thorotrast)|10|relative dose rate|Injection, intravenous| 600l from 895 l Th232|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-9-95|9|1112|Neoplasia benign|Other local manifestations and miscellaneus|back|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-1|10|491|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-2|10|504|Neoplasia malignant|Other local manifestations and miscellaneus|neck|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-3|10|526|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|anal,MPATH: 408 - soft tissue fibrosarcoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-4|10|590|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-5|10|590|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-6|10|591|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-7|10|618|Neoplasia malignant|Other local manifestations and miscellaneus|back|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-8|10|621|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-9|10|621|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-10|10|627|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-11|10|628|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-12|10|647|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|back,MPATH: 408 - soft tissue fibrosarcoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-13|10|649|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-14|10|657|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-15|10|663|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-16|10|671|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-17|10|675|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-18|10|677|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-19|10|709|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-20|10|716|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-21|10|719|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-22|10|732|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|eye,MPATH: 446 - squamous cell carcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-23|10|741|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-24|10|745|Neoplasia benign|Bloodvessels among cardiovascular system|lymphnode|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-25|10|753|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-26|10|755|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-27|10|767|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-28|10|774|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-29|10|777|Neoplasia malignant|Other local manifestations and miscellaneus|forelegs|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-30|10|777|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-31|10|779|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-32|10|786|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-33|10|795|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-34|10|799|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-35|10|802|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-36|10|805|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-37|10|817|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-38|10|823|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|horned,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-39|10|827|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-40|10|828|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-41|10|840|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-42|10|854|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-43|10|859|Neoplasia systemic|Haematolymphatic system|liver|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-44|10|860|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-45|10|866|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-46|10|869|Neoplasia systemic|Haematolymphatic system|liver|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-47|10|877|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-48|10|878|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-49|10|878|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-50|10|880|Neoplasia benign|Other local manifestations and miscellaneus|hyerplasia|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-51|10|883|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-52|10|884|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-53|10|885|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-54|10|890|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-55|10|899|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-56|10|904|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-57|10|910|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-58|10|910|Neoplasia unclassified|Peripheral nerves  among nervous system|head|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-59|10|924|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-60|10|930|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|anal,MPATH: 219 - adnexal and skin appendage tumor|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-61|10|943|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-62|10|946|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-63|10|946|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-64|10|949|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-65|10|950|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-66|10|956|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-67|10|964|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-68|10|965|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-69|10|969|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-70|10|970|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-71|10|971|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-72|10|975|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-73|10|978|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-74|10|980|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-75|10|982|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-76|10|989|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-77|10|992|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-78|10|992|Neoplasia benign|Integumentary system,MA: 0000151 - skin|hindlegs,MPATH: 407 - fibroma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-79|10|993|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-80|10|997|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-81|10|1001|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-82|10|1012|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-83|10|1025|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-84|10|1049|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-85|10|1066|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-86|10|1074|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-87|10|1082|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-88|10|1083|Other deterministic changes|Whole body|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-89|10|1089|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-90|10|1099|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-91|10|1107|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-92|10|1121|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-93|10|1155|Neoplasia benign|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 270 - adenoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-94|10|1208|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-95|10|1213|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-10|Th60-Do 2,n/a|1| 84|Th-230 + Th-232|2|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-10-96|10|1248|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-1|11|324|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-2|11|503|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-3|11|508|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-4|11|599|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-5|11|615|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-6|11|648|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-7|11|653|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-8|11|664|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-9|11|665|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-10|11|672|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-11|11|672|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-12|11|676|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-13|11|684|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|carcinosarcoma,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-14|11|688|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-15|11|695|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-16|11|696|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-17|11|701|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-18|11|703|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-19|11|714|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-20|11|716|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-21|11|728|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-22|11|746|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-23|11|748|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-24|11|748|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-25|11|752|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-26|11|753|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-27|11|766|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-28|11|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-29|11|778|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-30|11|783|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-31|11|784|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-32|11|784|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-33|11|801|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-34|11|801|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-35|11|802|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-36|11|810|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-37|11|810|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-38|11|811|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-39|11|813|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-40|11|818|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-41|11|825|Neoplasia benign|Lower digestive tract,MA: 0000328 - intestine|,MPATH: 270 - adenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-42|11|827|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-43|11|833|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-44|11|834|Neoplasia systemic|Haematolymphatic system|liver|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-45|11|836|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-46|11|842|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-47|11|857|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-48|11|859|Neoplasia benign|Integumentary system,MA: 0000151 - skin|ear,MPATH: 218 - neoplasm|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-49|11|866|Neoplasia malignant|Other local manifestations and miscellaneus|intestine|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-50|11|868|Neoplasia systemic|Haematolymphatic system|liver|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-51|11|871|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-52|11|891|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-53|11|891|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-54|11|893|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-55|11|896|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-56|11|915|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-57|11|918|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-58|11|919|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-59|11|929|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-60|11|934|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-61|11|936|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-62|11|944|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-63|11|950|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-64|11|959|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-65|11|964|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-66|11|964|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-67|11|985|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-68|11|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|forelegs,MPATH: 513 - Lymphoid neoplasms|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-69|11|992|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-70|11|1000|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-71|11|1021|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-72|11|1025|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|neck,MPATH: 446 - squamous cell carcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-73|11|1034|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-74|11|1036|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-75|11|1042|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-76|11|1043|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-77|11|1044|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-78|11|1046|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-79|11|1048|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-80|11|1052|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-81|11|1057|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-82|11|1060|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-83|11|1061|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-84|11|1077|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-85|11|1082|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-86|11|1083|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-87|11|1092|Other deterministic changes|Whole body|hindlegs|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-88|11|1100|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-89|11|1104|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-90|11|1106|Neoplasia benign|Other local manifestations and miscellaneus|ovary|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-91|11|1109|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-92|11|1137|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-93|11|1142|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-94|11|1182|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-95|11|1221|Other deterministic changes|Whole body|n/a|
4-1-11|Th120-Do 4,n/a|1| 84|Th-230 + Th-232|4|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 1650l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-11-96|11|1243|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-1|12|354|Neoplasia malignant|Heart among cardiovascular system,MA: 0000072 - heart|,MPATH: 511 - Myeloproliferation (genetic)|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-2|12|418|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-3|12|446|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-4|12|491|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-5|12|528|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-6|12|541|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-7|12|555|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-8|12|557|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-9|12|574|Neoplasia malignant|Other local manifestations and miscellaneus|foot|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-10|12|579|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-11|12|592|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-12|12|611|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|eye,MPATH: 446 - squamous cell carcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-13|12|613|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-14|12|613|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-15|12|618|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-16|12|641|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-17|12|646|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-18|12|654|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-19|12|674|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-20|12|678|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-21|12|678|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-22|12|679|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-23|12|694|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-24|12|704|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|anal,MPATH: 513 - Lymphoid neoplasms|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-25|12|705|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-26|12|708|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-27|12|709|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-28|12|712|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-29|12|712|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-30|12|718|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-31|12|719|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-32|12|725|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|foot,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-33|12|726|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-34|12|734|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-35|12|737|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|foot,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-36|12|737|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-37|12|739|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-38|12|741|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-39|12|748|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-40|12|751|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-41|12|753|Neoplasia benign|Other local manifestations and miscellaneus|cavity|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-42|12|754|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-43|12|759|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-44|12|762|Neoplasia benign|Bloodvessels among cardiovascular system|lymphnode|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-45|12|762|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-46|12|765|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-47|12|769|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-48|12|774|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-49|12|774|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-50|12|776|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-51|12|777|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-52|12|784|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-53|12|785|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-54|12|789|Neoplasia benign|Integumentary system,MA: 0000151 - skin|,MPATH: 218 - neoplasm|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-55|12|792|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-56|12|792|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-57|12|793|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-58|12|798|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-59|12|802|Neoplasia benign|Integumentary system,MA: 0000151 - skin|tail,MPATH: 407 - fibroma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-60|12|805|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-61|12|806|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-62|12|812|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-63|12|813|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-64|12|817|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-65|12|824|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-66|12|826|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-67|12|827|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-68|12|831|Neoplasia benign|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 270 - adenoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-69|12|834|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-70|12|834|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-71|12|842|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-72|12|847|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-73|12|847|Neoplasia benign|Integumentary system,MA: 0000151 - skin|hindlegs,MPATH: 407 - fibroma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-74|12|850|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-75|12|852|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-76|12|860|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-77|12|877|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-78|12|879|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|face,MPATH: 446 - squamous cell carcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-79|12|889|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-80|12|898|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-81|12|899|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|neck,MPATH: 446 - squamous cell carcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-82|12|899|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-83|12|913|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-84|12|915|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|anal,MPATH: 219 - adnexal and skin appendage tumor|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-85|12|920|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-86|12|936|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|anal,MPATH: 446 - squamous cell carcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-87|12|942|Other deterministic changes|Whole body|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-88|12|943|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-89|12|978|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-90|12|980|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-91|12|986|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-12|Th300-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 1650l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-12-92|12|1026|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-1|13|160|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-2|13|272|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-3|13|433|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-4|13|449|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-5|13|466|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-6|13|482|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-7|13|491|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-8|13|528|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-9|13|533|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-10|13|562|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-11|13|562|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-12|13|564|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-13|13|585|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-14|13|585|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-15|13|627|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|metastase,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-16|13|635|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-17|13|639|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-18|13|640|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-19|13|641|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-20|13|648|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-21|13|653|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-22|13|668|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-23|13|672|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-24|13|676|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-25|13|691|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-26|13|698|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-27|13|706|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-28|13|714|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-29|13|720|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-30|13|726|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-31|13|727|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-32|13|733|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-33|13|737|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-34|13|737|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-35|13|744|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-36|13|746|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-37|13|747|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-38|13|752|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-39|13|755|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-40|13|761|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-41|13|763|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-42|13|766|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-43|13|771|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-44|13|775|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-45|13|777|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-46|13|779|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-47|13|797|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-48|13|802|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-49|13|825|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-50|13|833|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-51|13|833|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-52|13|839|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-53|13|843|Neoplasia malignant|Other local manifestations and miscellaneus|forelegs|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-54|13|848|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-55|13|849|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-56|13|856|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-57|13|859|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-58|13|871|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-59|13|871|Neoplasia unclassified|Ovary among reproductive system diseases|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-60|13|871|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-61|13|873|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-62|13|878|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-63|13|882|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-64|13|889|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-65|13|889|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-66|13|899|Neoplasia benign|Bloodvessels among cardiovascular system|lymphnode|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-67|13|904|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-68|13|906|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-69|13|911|Neoplasia systemic|Haematolymphatic system|liver|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-70|13|920|Neoplasia unclassified|Peripheral nerves  among nervous system|intestine|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-71|13|928|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-72|13|930|Neoplasia benign|Other local manifestations and miscellaneus,MA: 0000003 - organ system|anal,MPATH: 507 - mast cell sarcoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-73|13|946|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-74|13|947|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-75|13|959|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-76|13|959|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-77|13|962|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-78|13|963|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-79|13|973|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-80|13|975|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-81|13|985|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-82|13|1008|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-83|13|1010|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|face,MPATH: 446 - squamous cell carcinoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-84|13|1021|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-85|13|1022|Neoplasia benign|Bloodvessels among cardiovascular system|cavity|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-86|13|1032|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-87|13|1050|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-88|13|1098|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-89|13|1120|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-90|13|1128|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-91|13|1137|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-92|13|1171|Neoplasia benign|Other local manifestations and miscellaneus|cavity|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-93|13|1181|Other deterministic changes|Whole body|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-94|13|1190|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-95|13|1213|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-13|Th60-Do 5,n/a|1| 84|Th-230 + Th-232|5|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 6550l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-13-96|13|1248|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-1|14|137|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-2|14|272|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-3|14|320|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-4|14|489|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-5|14|491|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-6|14|511|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-7|14|528|Neoplasia benign|Other local manifestations and miscellaneus|ovary|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-8|14|533|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-9|14|588|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-10|14|605|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-11|14|627|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-12|14|628|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-13|14|647|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-14|14|651|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-15|14|668|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-16|14|674|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-17|14|678|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-18|14|682|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-19|14|683|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-20|14|688|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-21|14|692|Neoplasia unclassified|Central nervous system among nervous system|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-22|14|701|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-23|14|718|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-24|14|725|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-25|14|734|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-26|14|744|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-27|14|747|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-28|14|754|Neoplasia malignant|Lower digestive tract,MA: 0000328 - intestine|,MPATH: 549 - carcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-29|14|762|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-30|14|769|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-31|14|775|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-32|14|776|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-33|14|777|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 270 - adenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-34|14|783|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-35|14|791|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-36|14|797|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-37|14|805|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-38|14|813|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-39|14|823|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-40|14|825|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-41|14|826|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|axilla,MPATH: 408 - soft tissue fibrosarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-42|14|826|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-43|14|834|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-44|14|836|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-45|14|840|Neoplasia unclassified|Central nervous system among nervous system|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-46|14|840|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-47|14|841|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|eye,MPATH: 446 - squamous cell carcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-48|14|848|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-49|14|848|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-50|14|855|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-51|14|863|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-52|14|866|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 270 - adenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-53|14|866|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-54|14|870|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-55|14|879|Neoplasia unclassified|Ovary among reproductive system diseases|cell|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-56|14|887|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-57|14|887|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-58|14|899|Neoplasia unclassified|Peripheral nerves  among nervous system|forelegs|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-59|14|904|Other deterministic changes|Whole body|forelegs|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-60|14|913|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-61|14|924|Neoplasia malignant|Other local manifestations and miscellaneus|eye|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-62|14|932|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-63|14|934|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-64|14|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-65|14|954|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-66|14|954|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-67|14|954|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-68|14|961|Neoplasia benign|Other local manifestations and miscellaneus|ovary|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-69|14|965|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-70|14|966|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-71|14|968|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-72|14|979|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-73|14|980|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|thorax,MPATH: 408 - soft tissue fibrosarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-74|14|986|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-75|14|999|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-76|14|1022|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-77|14|1026|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-78|14|1041|Other deterministic changes|Whole body|hindlegs|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-79|14|1044|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-80|14|1049|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-81|14|1050|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 551 - sarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-82|14|1055|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-83|14|1061|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-84|14|1062|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-85|14|1069|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-86|14|1077|Neoplasia benign|Other local manifestations and miscellaneus|ovary|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-87|14|1077|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-88|14|1077|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-89|14|1092|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-90|14|1099|Other deterministic changes|Whole body|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-91|14|1105|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-92|14|1106|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-14|Th120-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 6550l Th230|93 (93 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-14-93|14|1169|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-1|15|448|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-2|15|454|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-3|15|463|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-4|15|506|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-5|15|520|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-6|15|522|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-7|15|522|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-8|15|525|Other deterministic changes|Whole body|axilla|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-9|15|535|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-10|15|567|Neoplasia malignant|Other local manifestations and miscellaneus|anal|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-11|15|568|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-12|15|571|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-13|15|576|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-14|15|586|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-15|15|590|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-16|15|591|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-17|15|606|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-18|15|606|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-19|15|608|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-20|15|608|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-21|15|627|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-22|15|632|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|foot,MPATH: 513 - Lymphoid neoplasms|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-23|15|634|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-24|15|636|Neoplasia malignant|Other local manifestations and miscellaneus|forelegs|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-25|15|639|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-26|15|640|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|head,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-27|15|651|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-28|15|662|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-29|15|680|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|back,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-30|15|694|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 549 - carcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-31|15|697|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-32|15|702|Neoplasia benign|Other local manifestations and miscellaneus|cavity|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-33|15|702|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-34|15|703|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-35|15|708|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-36|15|712|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-37|15|726|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-38|15|726|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-39|15|726|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-40|15|745|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-41|15|746|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-42|15|748|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|Uterus tumor unbekannter Art,MPATH: 268 - adenocarcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-43|15|754|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-44|15|754|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|leg,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-45|15|755|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-46|15|759|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-47|15|760|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-48|15|769|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-49|15|771|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-50|15|771|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-51|15|774|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-52|15|777|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-53|15|777|Neoplasia malignant|Other local manifestations and miscellaneus|head|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-54|15|779|Neoplasia benign|Other local manifestations and miscellaneus|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-55|15|789|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-56|15|789|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-57|15|793|Other deterministic changes|Whole body|forelegs|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-58|15|795|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-59|15|795|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-60|15|798|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-61|15|818|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-62|15|821|Neoplasia benign|Other local manifestations and miscellaneus|anal|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-63|15|825|Neoplasia malignant|Other local manifestations and miscellaneus|hindlegs|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-64|15|833|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-65|15|838|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|head,MPATH: 446 - squamous cell carcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-66|15|838|Neoplasia unclassified|Peripheral nerves  among nervous system|head|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-67|15|846|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-68|15|849|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-69|15|853|Neoplasia unclassified|Nervous system and special sense organs,MA: 0000261 - eye|,MPATH: 218 - neoplasm|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-70|15|854|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-71|15|855|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-72|15|856|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-73|15|861|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-74|15|864|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-75|15|865|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-76|15|873|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-77|15|878|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-78|15|885|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-79|15|892|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-80|15|893|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|forelegs,MPATH: 513 - Lymphoid neoplasms|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-81|15|893|Neoplasia unclassified|Peripheral nerves  among nervous system|anal|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-82|15|896|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-83|15|905|Other deterministic changes|Whole body|forelegs|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-84|15|912|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-85|15|924|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-86|15|925|Neoplasia malignant|Other local manifestations and miscellaneus|neck|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-87|15|929|Neoplasia benign|Bloodvessels among cardiovascular system|haemangiopericytoma perit.cav.|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-88|15|948|Other deterministic changes|Whole body|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-89|15|985|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-90|15|992|Neoplasia unclassified|Ovary among reproductive system diseases,MA: 0002420 - gonad|sertolicell,MPATH: 332 - sertoli-leydig cell tumor|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-91|15|1053|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-15|Th300-Do 25,n/a|1| 84|Th-230 + Th-232|25|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 6550l Th230|92 (92 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-15-92|15|1055|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-1|16|324|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-2|16|449|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-3|16|479|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-4|16|501|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-5|16|512|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-6|16|516|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-7|16|536|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-8|16|546|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-9|16|565|Neoplasia benign|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 270 - adenoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-10|16|565|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-11|16|598|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-12|16|621|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-13|16|650|Neoplasia unclassified|Nervous system and special sense organs|cavity|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-14|16|658|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-15|16|658|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-16|16|662|Other deterministic changes|Whole body|anal|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-17|16|662|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-18|16|671|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-19|16|691|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-20|16|693|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-21|16|695|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-22|16|703|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-23|16|719|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-24|16|725|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-25|16|727|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-26|16|728|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-27|16|731|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-28|16|732|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-29|16|738|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-30|16|743|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|lymphnode,MPATH: 513 - Lymphoid neoplasms|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-31|16|750|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-32|16|756|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-33|16|757|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-34|16|760|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 255 - adenoacanthoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-35|16|775|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-36|16|780|Neoplasia benign|Lower respiratory system|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-37|16|782|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-38|16|785|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-39|16|785|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-40|16|785|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-41|16|790|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-42|16|790|Neoplasia malignant|Other local manifestations and miscellaneus|hindlegs|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-43|16|791|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-44|16|796|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|cavity,MPATH: 408 - soft tissue fibrosarcoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-45|16|803|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-46|16|806|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-47|16|806|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-48|16|813|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-49|16|827|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-50|16|833|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-51|16|834|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-52|16|843|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-53|16|849|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-54|16|857|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-55|16|857|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-56|16|860|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-57|16|863|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-58|16|869|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-59|16|876|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-60|16|879|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|forelegs,MPATH: 219 - adnexal and skin appendage tumor|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-61|16|885|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-62|16|886|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-63|16|887|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-64|16|891|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-65|16|899|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-66|16|900|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-67|16|901|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-68|16|905|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-69|16|914|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-70|16|919|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-71|16|952|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-72|16|955|Neoplasia systemic|Haematolymphatic system|liver|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-73|16|957|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-74|16|979|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-75|16|979|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-76|16|986|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-77|16|986|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-78|16|988|Neoplasia systemic|Haematolymphatic system|liver|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-79|16|997|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-80|16|1009|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-81|16|1013|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-82|16|1023|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-83|16|1027|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-84|16|1029|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-85|16|1034|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|carcinose,MPATH: 268 - adenocarcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-86|16|1041|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-87|16|1046|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-88|16|1046|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-89|16|1047|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-90|16|1049|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-91|16|1061|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-92|16|1065|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-93|16|1078|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-94|16|1100|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-95|16|1113|Other deterministic changes|Whole body|n/a|
4-1-16|Th60-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-16-96|16|1145|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-1|17|152|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-2|17|361|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000003 - organ system|femur,MPATH: 551 - sarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-3|17|411|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-4|17|415|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-5|17|455|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-6|17|468|Neoplasia malignant|Other local manifestations and miscellaneus|forelegs|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-7|17|483|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 235 - blood vessel tumor|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-8|17|542|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-9|17|549|Neoplasia systemic|Haematolymphatic system|liver|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-10|17|550|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-11|17|572|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-12|17|582|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-13|17|589|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-14|17|614|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-15|17|615|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-16|17|618|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-17|17|618|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-18|17|639|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-19|17|640|Neoplasia malignant|Other local manifestations and miscellaneus|anal|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-20|17|655|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-21|17|662|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-22|17|669|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-23|17|670|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-24|17|676|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-25|17|684|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-26|17|685|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|leg,MPATH: 408 - soft tissue fibrosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-27|17|685|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-28|17|691|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|leg,MPATH: 408 - soft tissue fibrosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-29|17|698|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-30|17|705|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|eye,MPATH: 446 - squamous cell carcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-31|17|707|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-32|17|721|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-33|17|727|Neoplasia benign|Bloodvessels among cardiovascular system|lymphnode|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-34|17|731|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-35|17|745|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-36|17|754|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-37|17|757|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-38|17|760|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-39|17|761|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-40|17|763|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-41|17|767|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-42|17|768|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-43|17|772|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-44|17|778|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-45|17|782|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-46|17|782|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-47|17|790|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-48|17|790|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-49|17|797|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-50|17|802|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-51|17|819|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-52|17|820|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-53|17|824|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-54|17|829|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-55|17|829|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-56|17|832|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-57|17|834|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-58|17|834|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-59|17|836|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-60|17|841|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-61|17|843|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-62|17|856|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-63|17|860|Neoplasia benign|Integumentary system,MA: 0000151 - skin|forelegs,MPATH: 407 - fibroma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-64|17|863|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-65|17|879|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-66|17|880|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-67|17|880|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-68|17|892|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-69|17|895|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-70|17|906|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-71|17|919|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-72|17|920|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-73|17|920|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-74|17|923|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-75|17|930|Neoplasia unclassified|Nervous system and special sense organs|adrenal|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-76|17|930|Neoplasia systemic|Haematolymphatic system|liver|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-77|17|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-78|17|937|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-79|17|940|Neoplasia benign|Integumentary system,MA: 0000151 - skin|hindlegs,MPATH: 407 - fibroma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-80|17|951|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-81|17|962|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-82|17|962|Other deterministic changes|Whole body|anal|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-83|17|976|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-84|17|976|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-85|17|976|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-86|17|993|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-87|17|994|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-88|17|1000|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|foot,MPATH: 408 - soft tissue fibrosarcoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-89|17|1049|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-90|17|1076|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-91|17|1103|Other deterministic changes|Whole body|n/a|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-92|17|1106|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-93|17|1145|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-17|Th120-Do 20,n/a|1| 84|Th-230 + Th-232|20|relative dose rate|Injection, intravenous| 120l from 895 l Th232 + 14760l Th230|94 (94 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-17-94|17|1301|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-1|18|232|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-2|18|303|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-3|18|309|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-4|18|355|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-5|18|420|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-6|18|420|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 235 - blood vessel tumor|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-7|18|442|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|inquinal,MPATH: 408 - soft tissue fibrosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-8|18|456|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-9|18|469|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 235 - blood vessel tumor|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-10|18|491|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-11|18|497|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-12|18|502|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-13|18|513|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-14|18|520|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-15|18|530|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-16|18|532|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-17|18|550|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-18|18|555|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-19|18|555|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-20|18|572|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-21|18|586|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-22|18|592|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-23|18|599|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-24|18|600|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 551 - sarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-25|18|601|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-26|18|613|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|axilla,MPATH: 446 - squamous cell carcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-27|18|614|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-28|18|614|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 235 - blood vessel tumor|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-29|18|619|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-30|18|621|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-31|18|622|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-32|18|622|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-33|18|622|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-34|18|626|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-35|18|635|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-36|18|656|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-37|18|657|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-38|18|661|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-39|18|664|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-40|18|665|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-41|18|668|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|face,MPATH: 408 - soft tissue fibrosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-42|18|680|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-43|18|682|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-44|18|685|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-45|18|685|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 235 - blood vessel tumor|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-46|18|698|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-47|18|705|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|hindlegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-48|18|705|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|hindlegs,MPATH: 446 - squamous cell carcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-49|18|706|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-50|18|707|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-51|18|709|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-52|18|710|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-53|18|711|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-54|18|712|Neoplasia benign|Lower respiratory system|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-55|18|713|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-56|18|714|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-57|18|720|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-58|18|721|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-59|18|729|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-60|18|742|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-61|18|743|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-62|18|745|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-63|18|747|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-64|18|749|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-65|18|750|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-66|18|750|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-67|18|754|Neoplasia malignant|Other local manifestations and miscellaneus|forelegs|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-68|18|755|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 235 - blood vessel tumor|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-69|18|768|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-70|18|772|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-71|18|776|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-72|18|776|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-73|18|776|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-74|18|778|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-75|18|789|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-76|18|793|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-77|18|796|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-78|18|806|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-79|18|811|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-80|18|818|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-81|18|820|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-82|18|833|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-83|18|835|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-84|18|839|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-85|18|841|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-86|18|844|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-87|18|853|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-88|18|860|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-89|18|863|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-90|18|866|Neoplasia benign|Integumentary system,MA: 0000151 - skin|inquinal,MPATH: 218 - neoplasm|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-91|18|876|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-92|18|904|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-93|18|914|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-94|18|914|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-95|18|925|Other deterministic changes|Whole body|n/a|
4-1-18|Th300-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 300l from 895 l Th232 + 14760l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-18-96|18|926|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-1|19|413|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-2|19|445|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-3|19|562|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-4|19|564|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-5|19|565|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-6|19|594|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-7|19|594|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-8|19|605|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-9|19|669|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000003 - organ system|ribs,MPATH: 551 - sarcoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-10|19|673|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-11|19|684|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-12|19|696|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|leg,MPATH: 408 - soft tissue fibrosarcoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-13|19|698|Other deterministic changes|Other local manifestations and miscellaneus|xanthogranulomatosis|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-14|19|699|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-15|19|700|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-16|19|705|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-17|19|710|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-18|19|712|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-19|19|713|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-20|19|718|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-21|19|734|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-22|19|735|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-23|19|735|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-24|19|742|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-25|19|745|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-26|19|747|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-27|19|755|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-28|19|760|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-29|19|760|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-30|19|770|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-31|19|770|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|forelegs,MPATH: 446 - squamous cell carcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-32|19|770|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-33|19|775|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-34|19|777|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-35|19|778|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-36|19|790|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-37|19|792|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-38|19|794|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-39|19|813|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-40|19|815|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-41|19|817|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-42|19|820|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-43|19|826|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-44|19|827|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-45|19|827|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-46|19|831|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-47|19|832|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-48|19|856|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 425 - leiomyoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-49|19|857|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-50|19|871|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-51|19|880|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-52|19|885|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-53|19|887|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-54|19|892|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 551 - sarcoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-55|19|897|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|polyp,MPATH: 218 - neoplasm|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-56|19|900|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-57|19|902|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-58|19|905|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-59|19|911|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-60|19|911|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-61|19|920|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-62|19|927|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-63|19|930|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-64|19|934|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-65|19|936|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-66|19|937|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-67|19|937|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-68|19|944|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-69|19|951|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-70|19|951|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-71|19|951|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-72|19|952|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-73|19|976|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-74|19|985|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-75|19|995|Neoplasia benign|Other local manifestations and miscellaneus|ovary|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-76|19|1014|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-77|19|1015|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-78|19|1019|Neoplasia benign|Liver among hepato-pancreatic system diseases|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-79|19|1020|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|lipoma,MPATH: 218 - neoplasm|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-80|19|1020|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-81|19|1023|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-82|19|1042|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-83|19|1044|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-84|19|1054|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-85|19|1069|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-86|19|1072|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-87|19|1078|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-88|19|1098|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-89|19|1103|Neoplasia unclassified|Ovary among reproductive system diseases|cell|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-90|19|1113|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 266 - fibroadenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-91|19|1144|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-92|19|1149|Neoplasia unclassified|Ovary among reproductive system diseases|cell|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-93|19|1151|Neoplasia benign|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 270 - adenoma|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-94|19|1154|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-95|19|1156|Other deterministic changes|Whole body|n/a|
4-1-19|Th12-Do 10,n/a|1| 84|Th-230 + Th-232|10|relative dose rate|Injection, intravenous| 12l from 895 l Th232 + 30360l Th230|96 (96 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-19-96|19|1201|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-1|20|234|Neoplasia unclassified|Peripheral nerves  among nervous system|cavity|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-2|20|266|Neoplasia malignant|Other local manifestations and miscellaneus|hindlegs|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-3|20|275|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-4|20|287|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-5|20|360|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-6|20|403|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-7|20|477|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|cavity,MPATH: 408 - soft tissue fibrosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-8|20|491|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-9|20|520|Neoplasia systemic|Haematolymphatic system|liver|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-10|20|521|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-11|20|525|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-12|20|527|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-13|20|528|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-14|20|541|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-15|20|545|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-16|20|563|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-17|20|563|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-18|20|569|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-19|20|585|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-20|20|596|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-21|20|596|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-22|20|607|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-23|20|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|liver,MPATH: 513 - Lymphoid neoplasms|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-24|20|628|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-25|20|634|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-26|20|636|Neoplasia malignant|Other local manifestations and miscellaneus|anal|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-27|20|651|Neoplasia malignant|Other local manifestations and miscellaneus|head|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-28|20|651|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-29|20|651|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-30|20|654|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 551 - sarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-31|20|661|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-32|20|664|Neoplasia benign|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 266 - fibroadenoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-33|20|667|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-34|20|671|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-35|20|683|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-36|20|685|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|anal,MPATH: 408 - soft tissue fibrosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-37|20|687|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-38|20|697|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-39|20|698|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-40|20|702|Neoplasia malignant|Bone among musculo-skeletal system diseases,MA: 0000018 - skeletal system|,MPATH: 551 - sarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-41|20|710|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-42|20|713|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-43|20|714|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-44|20|717|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-45|20|730|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-46|20|735|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-47|20|742|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-48|20|746|Neoplasia benign|Lower respiratory system|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-49|20|748|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-50|20|754|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-51|20|755|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-52|20|758|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-53|20|758|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-54|20|763|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-55|20|768|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-56|20|769|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-57|20|781|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-58|20|785|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-59|20|789|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-60|20|789|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-61|20|795|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-62|20|795|Neoplasia benign|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 240 - hemangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-63|20|798|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-64|20|803|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-65|20|804|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-66|20|816|Neoplasia benign|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 543 - cholangioma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-67|20|818|Neoplasia benign|Bloodvessels among cardiovascular system|skin|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-68|20|826|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-69|20|830|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|fibroma,MPATH: 218 - neoplasm|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-70|20|841|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-71|20|846|Neoplasia systemic|Haematolymphatic system|liver|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-72|20|847|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-73|20|848|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-74|20|849|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|adenoma,MPATH: 218 - neoplasm|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-75|20|849|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-76|20|856|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-77|20|868|Other deterministic changes|Whole body|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-78|20|877|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|tail,MPATH: 408 - soft tissue fibrosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-79|20|878|Neoplasia malignant|Other local manifestations and miscellaneus|hindlegs|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-80|20|878|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-81|20|880|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-82|20|883|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-83|20|885|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-84|20|893|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-85|20|898|Neoplasia malignant|Uterus among reproductive system diseases,MA: 0000389 - uterus|,MPATH: 268 - adenocarcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-86|20|899|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-87|20|901|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|spleen,MPATH: 513 - Lymphoid neoplasms|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-88|20|904|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-89|20|910|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-90|20|912|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-91|20|917|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-92|20|946|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-93|20|1046|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|forelegs,MPATH: 408 - soft tissue fibrosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-94|20|1050|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|axilla,MPATH: 408 - soft tissue fibrosarcoma|
4-1-20|Th60-Do 50,n/a|1| 84|Th-230 + Th-232|50|relative dose rate|Injection, intravenous| 60l from 895 l Th232 + 30360l Th230|95 (95 in ERA)|Rat|Rat Wistar|Female|Young Adult|Lifespan study with macroscopic/microscopic pathology|4-1-20-95|20|1069|Neoplasia unclassified|Peripheral nerves  among nervous system|tail|
		
